



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Long-Acting Injectable Antipsychotics

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Form with two columns: Patient Name and Prescriber Name. Fields include HPP Member Number, Date of Birth, Address, City, State ZIP, Patient Primary Phone, Line of Business (Medicaid, CHIP), Fax, Office Contact, NPI, Promise ID, Prescriber PA PROMISe ID, Address, City, State ZIP, and Specialty/facility name (if applicable).

Expedited/Urgent checkbox

Drug Name:

Strength:

Days Supply:

Number of Refills:

Directions / SIG:

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is the patient over the age of 18?

Yes checkbox

No checkbox

Q2. Does the patient have a diagnosis of schizophrenia, schizoaffective disorder (only if requested medication is Invega Sustenna) or bipolar disorder (only if requested medication is Risperdal Consta or Abilify Maintena)?

Yes checkbox

No checkbox

Q3. Has the patient been started and stabilized on treatment with the requested long acting injectable antipsychotic? Please provide documentation with date of last injection.

Yes checkbox

No checkbox

Q4. Is this request for Invega Trinza?

Yes checkbox

No checkbox

Q5. Has the patient been stabilized on Invega Sustenna (78 mg, 117 mg, 156 mg, or 234 mg) for at least 4 months and receiving the same dose for at least the last two doses?

Yes checkbox

No checkbox

Q6. Is the request for Risperdal Consta, Invega Sustenna, or Abilify Maintena OR has the patient failed treatment with the listed preferred alternatives? Please attach documentation of failure to preferred injectable antipsychotics with dates of trial.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



**HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM**

Health Partners Plans

Long-Acting Injectable Antipsychotics

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q7. Has the patient tolerated treatment with oral aripiprazole, oral risperidone, or oral ziprasidone (based on requested injectable antipsychotic) without side effects?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q8. Has the patient had repeat relapses (e.g. hospital admissions) related to diagnosis? Please indicate dates and duration.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q9. Does the patient have a history of long-term non-compliance with oral antipsychotic medication and/or a documented medical reason which would prevent the patient from using oral formulary atypical antipsychotic medication?	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q10. Has the patient failed measures (such as providing patient with instructions and problem-solving strategies such as reminders, self-monitoring tools, cues, and reinforcements) to improve compliance with formulary oral medications? Please document which adherence measures were done to improve compliance.	
<input type="checkbox"/> Yes	<input type="checkbox"/> No
Q11. Requested Duration:	
<input type="checkbox"/> 12 Months	
Q12. Additional Information:	

Prescriber Signature

Date

Updated 2018

